Vital Signs - Drug Development Focus on Genetically Modified Swine

Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs

USD 450

* Required Fields

USD 450

PAY BY INVOICE

Be the first to review this product

The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states and their physiological responses to treatment. Swine have been increasingly used as the animal model of choice because their anatomy, genetics, and physiology are more similar to humans than traditional animal models such as mice.

Table of Contents

Vital Signs - Drug Development Focus on Genetically Modified SwineVital Signs - February 2016February 2016 Issue




Related Research

Release Date : 15-Sep-17

Region : North America

Release Date : 15-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Release Date : 13-Sep-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.